A URAT1 antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Dotinurad

Item No. 41014

Technical Information
Formal Name
(3,5-dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2H)-benzothiazolyl)-methanone
CAS Number
1285572-51-1
Synonyms
  • FYU-981
Molecular Formula
C14H9Cl2NO4S
Formula Weight
Purity
≥98%
Formulation
A solid
DMSO: Sparingly Soluble: 1-10 mg/ml
SMILES
O=C(N1C2=C(S(=O)(C1)=O)C=CC=C2)C3=CC(Cl)=C(C(Cl)=C3)O
InChi Code
InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2
InChi Key
VOFLAIHEELWYGO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Product Description

    Dotinurad is a urate transporter 1 (URAT1) antagonist (IC50 = 0.0372 µM).1 It is selective for URAT1 over ATP-binding cassette subfamily G member 2 (ABCG2), organic anion transporter 1 (OAT1), and OAT3 (IC50s = 4.16, 4.08, and 1.32 µM, respectively). In vivo, dotinurad (30 mg/kg) decreases plasma levels of urate and increases urine levels of urate in Cebus monkeys. Formulations containing dotinurad have been used in the treatment of hyperuricemia and gout.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Taniguchi, T., Ashizawa, N., Matsumoto, K., et alPharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J. Pharmacol. Exp. Ther. 371(1), 162-170 (2019).